OLUMIANT (Eli Lilly Australia Pty Ltd)
Product name
OLUMIANT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
163 working days (255)
Active ingredients
baricitinib
Registration type
NCE/NBE
Indication
OLUMIANT is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately, or who are intolerant, to one or more disease-modifying anti-rheumatic drugs (DMARDs). OLUMIANT can be taken as monotherapy or in combination with conventional DMARDs, including methotrexate (MTX).